微信公众号

官网二维码

中国癌症防治杂志

• 论文 • 上一篇    下一篇

晚期黑色素瘤免疫综合治疗的临床分析

蒙志斌;余彬彬;欧盛秋;曾爱屏;   

  1. 广西医科大学肿瘤医院介入治疗科;
  • 收稿日期:2009-09-25 修回日期:2009-09-25 出版日期:2009-09-25 发布日期:2009-09-25

Clinical analysis of treating advanced melanoma with comprehensive immunotherapy

MENG Zhi-bin,YU Bin-bin,OU Sheng-qiu,et al.   

  1. (Department of Intervention Therapy,Guangxi Tumor Hospital,Nanning 530021,China
  • Received:2009-09-25 Revised:2009-09-25 Online:2009-09-25 Published:2009-09-25

摘要: 目的探讨自体黑色素瘤冷冻免疫瘤苗激活自体肿瘤浸润性淋巴细胞(TIL)对Ⅲ期黑色素瘤的临床疗效。方法将42例Ⅲ期黑色素瘤患者随机分为治疗组(n=22)和对照组(n=20),分别接受TIL+白介素-2(IL-2)和IL-2治疗2个月,并进行随访,观察两组的总体生存率(OS)和无复发生存率(RFS)以及治疗副反应。结果两组的OS和RFS比较,差异均无统计学意义(P>0.05);治疗组中1个淋巴结侵犯者的OS和RFS均比对照组显著改善,差异有统计学意义(P<0.05);两组患者均耐受治疗良好,副反应比较,差异无统计学意义(P>0.05)。结论TIL+IL-2治疗能显著改善Ⅲ期黑色素瘤患者的OS和RFS,只有1个淋巴结侵犯者治疗效果比>1个淋巴结侵犯者好。

关键词: 黑色素瘤, 肿瘤浸润细胞, 白介素-2

Abstract: Objective To investigate the effect of tumor infiltrating lymphocytes(TIL) stimulated by frozen tumor vaccine on melanoma stage Ⅲ.Methods 42 patients with melanoma stage Ⅲ were divided randomly into treatment group(TIL+IL-2,n=22) and control group(IL-2,n=20).All the patients in both groups were treated for 2 months.The overall survival(OS),relapse-free survival(RFS) and side effect of two groups were compared.Results The OS and RFS showed no significant difference between the treatment group and control group(P>0.05).The RFS and OS from the patients with only one invaded lymph node in treatment group improved significantly than that in control group(all P<0.05).All patients in both groups were well tolerated to the treatments.Conclusions TIL+IL-2 can significantly improve the OS and RFS of patients with melanoma stage Ⅲ.The treatment effect on the patient with only one invaded lymph node is better than that with more than one invaded lymph node.

Key words: Melanoma, Tumor infiltrating lymphocytes, Interleukin-2, Treatment